{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:40:50Z","timestamp":1785328850120,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bayer"},{"name":"BMS-Pfizerx"},{"name":"Daiichi-Sankyo"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03356-7","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:23:11Z","timestamp":1783621391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antiplatelet effects of oral anticoagulants in patients with atrial fibrillation: ex-vivo studies"],"prefix":"10.1007","author":[{"given":"Giulia","family":"Renda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bucciarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Lanuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Berteotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gelsomina","family":"Malatesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betti","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"3","key":"3356_CR1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/rth2.12107","volume":"2","author":"F Swieringa","year":"2018","unstructured":"Swieringa F, Spronk HMH, Heemskerk JWM, van der Meijden PEJ (2018) Integrating platelet and coagulation activation in fibrin clot formation. Res Pract Thromb Haemost 2(3):450\u2013460. https:\/\/doi.org\/10.1002\/rth2.12107","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"3356_CR2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/eurheartj\/ehae776","volume":"46","author":"G Vilahur","year":"2025","unstructured":"Vilahur G, Fuster V (2025) Interplay between platelets and coagulation: from protective haemostasis to pathological arterial thrombosis. Eur Heart J 46(5):413\u2013423. https:\/\/doi.org\/10.1093\/eurheartj\/ehae776","journal-title":"Eur Heart J"},{"issue":"2","key":"3356_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000073849","volume":"33","author":"M Wolzt","year":"2003","unstructured":"Wolzt M, Bostrom SL, Svensson M, Wahlander K, Grind M, Sarich TC (2003) Effects of the oral direct thrombin inhibitor ximelagatran on p-selectin expression and thrombin generation in atrial fibrillation. Pathophysiol Haemost Thromb 33(2):68\u201374. https:\/\/doi.org\/10.1159\/000073849","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"2","key":"3356_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/01.mbc.0000046190.72384.8c","volume":"14","author":"S Nylander","year":"2003","unstructured":"Nylander S, Mattsson C (2003) Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action. Blood Coagul Fibrinolysis 14(2):159\u2013167. https:\/\/doi.org\/10.1097\/01.mbc.0000046190.72384.8c","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"6","key":"3356_CR5","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1177\/1074248415578172","volume":"20","author":"E Perzborn","year":"2015","unstructured":"Perzborn E, Heitmeier S, Laux V (2015) Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: in vitro and in vivo studies. J Cardiovasc Pharmacol Ther 20(6):554\u2013562. https:\/\/doi.org\/10.1177\/1074248415578172","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"6","key":"3356_CR6","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.thromres.2015.03.032","volume":"135","author":"A Tripodi","year":"2015","unstructured":"Tripodi A, Padovan L, Veena C, Scalambrino E, Testa S, Peyvandi F (2015) How the direct oral anticoagulant apixaban affects thrombin generation parameters. Thromb Res 135(6):1186\u20131190. https:\/\/doi.org\/10.1016\/j.thromres.2015.03.032","journal-title":"Thromb Res"},{"issue":"8","key":"3356_CR7","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1097\/MBC.0000000000000509","volume":"27","author":"H Wan","year":"2016","unstructured":"Wan H, Yang Y, Zhu J, Wu S, Zhou Z, Huang B, Wang J, Shao X, Zhang H (2016) An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban. Blood Coagul Fibrinolysis 27(8):882\u2013885. https:\/\/doi.org\/10.1097\/MBC.0000000000000509","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"3356_CR8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1160\/TH13-07-0607","volume":"111","author":"R Herrmann","year":"2014","unstructured":"Herrmann R, Thom J, Wood A, Phillips M, Muhammad S, Baker R (2014) Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost 111(5):989\u2013995. https:\/\/doi.org\/10.1160\/TH13-07-0607","journal-title":"Thromb Haemost"},{"issue":"4","key":"3356_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/14017431.2018.1480798","volume":"52","author":"J Sokol","year":"2018","unstructured":"Sokol J, Nehaj F, Ivankova J, Mokan M, Mokan M, Stasko J (2018) Dabigatran affects thrombin-dependent platelet aggregation after a week-long therapy. Scand Cardiovasc J 52(4):227\u2013231. https:\/\/doi.org\/10.1080\/14017431.2018.1480798","journal-title":"Scand Cardiovasc J"},{"issue":"3","key":"3356_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s11239-018-1709-z","volume":"46","author":"J Sokol","year":"2018","unstructured":"Sokol J, Nehaj F, Ivankova J, Mokan M, Mokan M (2018) First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation. J Thromb Thrombolysis 46(3):393\u2013398. https:\/\/doi.org\/10.1007\/s11239-018-1709-z","journal-title":"J Thromb Thrombolysis"},{"key":"3356_CR11","doi-asserted-by":"publisher","unstructured":"Sokol J, Nehaj F, Ivankova J, Mokan M, Lisa L, Zolkova J, Vadelova L, Mokan M, Stasko J (2020) Impact of edoxaban on thrombin-dependent platelet aggregation. Clin Appl Thromb Hemost 26(1076029620948585). https:\/\/doi.org\/10.1177\/1076029620948585","DOI":"10.1177\/1076029620948585"},{"issue":"2","key":"3356_CR12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1177\/1076029617713871","volume":"24","author":"F Nehaj","year":"2018","unstructured":"Nehaj F, Sokol J, Mokan M, Ivankova J, Mokan M (2018) Thrombin receptor agonist peptide-induced platelet aggregation is reduced in patients receiving dabigatran. Clin Appl Thromb Hemost 24(2):268\u2013272. https:\/\/doi.org\/10.1177\/1076029617713871","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"3356_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11239-016-1350-7","volume":"42","author":"CB Olivier","year":"2016","unstructured":"Olivier CB, Weik P, Meyer M, Weber S, Diehl P, Bode C, Moser M, Zhou Q (2016) Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors. J Thromb Thrombolysis 42(2):161\u2013166. https:\/\/doi.org\/10.1007\/s11239-016-1350-7","journal-title":"J Thromb Thrombolysis"},{"key":"3356_CR14","doi-asserted-by":"publisher","unstructured":"Gomes Taques Baldo V, Bertolin A, Sarti D, Diez Andrade M, Ribeiro A, Caporrino Pereira C, Suzuki K, Melo R, Lima F, Baracioli L et al (2025) Effects of edoxaban on platelet reactivity in patients with coronary artery disease. JACC 85:1888 https:\/\/doi.org\/10.1016\/S0735-1097(25)02372-1","DOI":"10.1016\/S0735-1097(25)02372-1"},{"key":"3356_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.thromres.2016.02.028","volume":"141","author":"Y Honda","year":"2016","unstructured":"Honda Y, Kamisato C, Morishima Y (2016) Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux. Thromb Res 141:17\u201321. https:\/\/doi.org\/10.1016\/j.thromres.2016.02.028","journal-title":"Thromb Res"},{"issue":"3","key":"3356_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11239-012-0727-5","volume":"34","author":"SM Ringwala","year":"2012","unstructured":"Ringwala SM, Dibattiste PM, Schneider DJ (2012) Effects on platelet function of a direct acting antagonist of coagulation factor Xa. J Thromb Thrombolysis 34(3):291\u2013296. https:\/\/doi.org\/10.1007\/s11239-012-0727-5","journal-title":"J Thromb Thrombolysis"},{"key":"3356_CR17","doi-asserted-by":"crossref","unstructured":"van Ryn J, Kink-Eiband M, Hauel N, Priepke H, W W (2007) Effects of dabigatran, a direct thrombin inhibitor, as compared to the direct factor Xa inhibitors, rivaroxaban and apixaban, on tissue factor-induced human platelet aggregation in platelet rich plasma. In: Blood, p 1884","DOI":"10.1182\/blood.V110.11.1884.1884"},{"issue":"2","key":"3356_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s11239-017-1512-2","volume":"44","author":"PJ Vinholt","year":"2017","unstructured":"Vinholt PJ, Nielsen C, Soderstrom AC, Brandes A, Nybo M (2017) Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner. J Thromb Thrombolysis 44(2):216\u2013222. https:\/\/doi.org\/10.1007\/s11239-017-1512-2","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"3356_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1124\/mol.114.096446","volume":"88","author":"B Chen","year":"2015","unstructured":"Chen B, Soto AG, Coronel LJ, Goss A, van Ryn J, Trejo J (2015) Characterization of thrombin-bound dabigatran effects on protease-activated receptor-1 expression and signaling in vitro. Mol Pharmacol 88(1):95\u2013105. https:\/\/doi.org\/10.1124\/mol.114.096446","journal-title":"Mol Pharmacol"},{"issue":"3","key":"3356_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/jth.13595","volume":"15","author":"A Achilles","year":"2017","unstructured":"Achilles A, Mohring A, Dannenberg L, Grandoch M, Hohlfeld T, Fischer JW, Levkau B, Kelm M, Zeus T, Polzin A (2017) Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation. J Thromb Haemost 15(3):473\u2013476. https:\/\/doi.org\/10.1111\/jth.13595","journal-title":"J Thromb Haemost"},{"key":"3356_CR21","doi-asserted-by":"publisher","unstructured":"Jannati S, Patnaik R, Banerjee Y (2024) Beyond Anticoagulation: A comprehensive review of non-vitamin K oral anticoagulants (NOACs) in inflammation and protease-activated receptor signaling. Int J Mol Sci 25(16). https:\/\/doi.org\/10.3390\/ijms25168727","DOI":"10.3390\/ijms25168727"},{"issue":"2","key":"3356_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s00399-023-00944-5","volume":"34","author":"A Goette","year":"2023","unstructured":"Goette A, Mollenhauer M, Rudolph V, Lamparter M, Meier M, Bohm M (2023) Pleiotropic effects of NOACs with focus on edoxaban: scientific findings and potential clinical implications. Herzschrittmacherther Elektrophysiol 34(2):142\u2013152. https:\/\/doi.org\/10.1007\/s00399-023-00944-5","journal-title":"Herzschrittmacherther Elektrophysiol"},{"key":"3356_CR23","doi-asserted-by":"publisher","unstructured":"Renda G, Bucciarelli V, Barbieri G, Lanuti P, Berteotti M, Malatesta G, Cesari F, Salvatore T, Giusti B, Gori AM et al (2024) Ex vivo antiplatelet effects of oral anticoagulants. J Cardiovasc Dev Dis 11(4). https:\/\/doi.org\/10.3390\/jcdd11040111","DOI":"10.3390\/jcdd11040111"},{"issue":"5","key":"3356_CR24","first-page":"553","volume":"96","author":"HC Hemker","year":"2006","unstructured":"Hemker HC, Al Dieri R, De Smedt E, Beguin S (2006) Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 96(5):553\u2013561","journal-title":"Thromb Haemost"},{"key":"3356_CR25","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/194927b0","volume":"194","author":"GV Born","year":"1962","unstructured":"Born GV (1962) Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194:927\u2013929. https:\/\/doi.org\/10.1038\/194927b0","journal-title":"Nature"},{"issue":"24","key":"3356_CR26","doi-asserted-by":"publisher","first-page":"21173","DOI":"10.1074\/jbc.M008249200","volume":"276","author":"G Soslau","year":"2001","unstructured":"Soslau G, Class R, Morgan DA, Foster C, Lord ST, Marchese P, Ruggeri ZM (2001) Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib. J Biol Chem 276(24):21173\u201321183. https:\/\/doi.org\/10.1074\/jbc.M008249200","journal-title":"J Biol Chem"},{"issue":"2","key":"3356_CR27","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s11239-020-02334-x","volume":"51","author":"PA Gurbel","year":"2021","unstructured":"Gurbel PA, Bliden KP, Tantry US (2021) Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B(2) and agonist-induced platelet aggregation. J Thromb Thrombolysis 51(2):260\u2013264. https:\/\/doi.org\/10.1007\/s11239-020-02334-x","journal-title":"J Thromb Thrombolysis"},{"issue":"10","key":"3356_CR28","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/eji.201970107","volume":"49","author":"A Cossarizza","year":"2019","unstructured":"Cossarizza A, Chang HD, Radbruch A, Acs A, Adam D, Adam-Klages S, Agace WW, Aghaeepour N, Akdis M, Allez M et al (2019) Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). Eur J Immunol 49(10):1457\u20131973. https:\/\/doi.org\/10.1002\/eji.201970107","journal-title":"Eur J Immunol"},{"key":"3356_CR29","doi-asserted-by":"publisher","unstructured":"Gribkova IV, Lipets EN, Rekhtina IG, Bernakevich AI, Ayusheev DB, Ovsepyan RA, Ataullakhanov FI, Sinauridze EI (2016) The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency. Sci Rep 6(29242). https:\/\/doi.org\/10.1038\/srep29242","DOI":"10.1038\/srep29242"},{"issue":"11","key":"3356_CR30","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1515\/cclm-2014-0307","volume":"52","author":"J Dinkelaar","year":"2014","unstructured":"Dinkelaar J, Patiwael S, Harenberg J, Leyte A, Brinkman HJ (2014) Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate. Clin Chem Lab Med 52(11):1615\u20131623. https:\/\/doi.org\/10.1515\/cclm-2014-0307","journal-title":"Clin Chem Lab Med"},{"key":"3356_CR31","doi-asserted-by":"publisher","unstructured":"Meihandoest T, Studt JD, Mendez A, Alberio L, Fontana P, Wuillemin WA, Schmidt A, Graf L, Gerber B, Maeder GM et al (2021) Automated Thrombin generation assay for Rivaroxaban, Apixaban, and Edoxaban measurements. Front Cardiovasc Med 8(717939). https:\/\/doi.org\/10.3389\/fcvm.2021.717939","DOI":"10.3389\/fcvm.2021.717939"},{"key":"3356_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.thromres.2019.03.022","volume":"178","author":"DE Schmidt","year":"2019","unstructured":"Schmidt DE, Chaireti R, Bruzelius M, Holmstrom M, Antovic J, Agren A (2019) Correlation of thromboelastography and thrombin generation assays in warfarin-treated patients. Thromb Res 178:34\u201340. https:\/\/doi.org\/10.1016\/j.thromres.2019.03.022","journal-title":"Thromb Res"},{"key":"3356_CR33","doi-asserted-by":"publisher","unstructured":"Tripodi A, Capecchi M, Scalambrino E, Clerici M, Scimeca B, Agosti P, Bucciarelli P, Artoni A, Peyvandi F (2024) Comparative investigation of thromboelastometry and Thrombin generation for patients receiving direct oral anticoagulants or vitamin K antagonists. Diagnostics (Basel) 14(22). https:\/\/doi.org\/10.3390\/diagnostics14222553","DOI":"10.3390\/diagnostics14222553"},{"issue":"2","key":"3356_CR34","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/rth2.12044","volume":"1","author":"R Artang","year":"2017","unstructured":"Artang R, Anderson M, Riley P, Nielsen JD (2017) Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay. Res Pract Thromb Haemost 1(2):194\u2013201. https:\/\/doi.org\/10.1002\/rth2.12044","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"3356_CR35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2450\/2021.0153-21","volume":"20","author":"L Dirienzo","year":"2022","unstructured":"Dirienzo L, Vitulli A, Mancazzo F, Ammollo CT, Dellanoce C, Paoletti O, Testa S, Colucci M (2022) Differential effect of direct oral anticoagulants on thrombin generation and fibrinolysis in patients with atrial fibrillation and venous thromboembolism. Blood Transfus 20(6):505\u2013515. https:\/\/doi.org\/10.2450\/2021.0153-21","journal-title":"Blood Transfus"},{"issue":"4","key":"3356_CR36","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1160\/TH09-03-0176","volume":"103","author":"MM Samama","year":"2010","unstructured":"Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E (2010) Assessment of laboratory assays to measure rivaroxaban\u2013an oral, direct factor Xa inhibitor. Thromb Haemost 103(4):815\u2013825. https:\/\/doi.org\/10.1160\/TH09-03-0176","journal-title":"Thromb Haemost"},{"issue":"4","key":"3356_CR37","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/j.thromres.2011.07.026","volume":"129","author":"MM Samama","year":"2012","unstructured":"Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S (2012) In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res 129(4):e77\u201382. https:\/\/doi.org\/10.1016\/j.thromres.2011.07.026","journal-title":"Thromb Res"},{"issue":"4","key":"3356_CR38","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s11239-020-02093-9","volume":"49","author":"F Nehaj","year":"2020","unstructured":"Nehaj F, Sokol J, Ivankova J, Mokan M, Mokan M, Stasko J (2020) Edoxaban affects TRAP-dependent platelet aggregation. J Thromb Thrombolysis 49(4):578\u2013583. https:\/\/doi.org\/10.1007\/s11239-020-02093-9","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"3356_CR39","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1177\/1076029617734310","volume":"24","author":"F Nehaj","year":"2018","unstructured":"Nehaj F, Sokol J, Ivankova J, Mokan M, Kovar F, Stasko J, Mokan M (2018) First evidence: TRAP-induced platelet aggregation is reduced in patients receiving Xabans. Clin Appl Thromb Hemost 24(6):914\u2013919. https:\/\/doi.org\/10.1177\/1076029617734310","journal-title":"Clin Appl Thromb Hemost"},{"issue":"9892","key":"3356_CR40","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","volume":"382","author":"GW Stone","year":"2013","unstructured":"Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E et al (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382(9892):614\u2013623. https:\/\/doi.org\/10.1016\/S0140-6736(13)61170-8","journal-title":"Lancet"},{"key":"3356_CR41","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.thromres.2021.02.019","volume":"201","author":"K Oi","year":"2021","unstructured":"Oi K, Shimizu M, Natori T, Tsuda K, Yoshida M, Kamada A, Ishigaku Y, Narumi S, Oura K, Maeda T et al (2021) Influence of PAR-1 in patients with non-valvular atrial fibrillation: The antiplatelet effect of dabigatran. Thromb Res 201:123\u2013130. https:\/\/doi.org\/10.1016\/j.thromres.2021.02.019","journal-title":"Thromb Res"},{"issue":"Pt A","key":"3356_CR42","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.phrs.2016.09.035","volume":"113","author":"P Pignatelli","year":"2016","unstructured":"Pignatelli P, Pastori D, Bartimoccia S, Menichelli D, Vicario T, Nocella C, Carnevale R, Violi F (2016) Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding. Pharmacol Res 113(Pt A):484\u2013489. https:\/\/doi.org\/10.1016\/j.phrs.2016.09.035","journal-title":"Pharmacol Res"},{"issue":"3","key":"3356_CR43","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.ahj.2015.05.011","volume":"170","author":"D Pastori","year":"2015","unstructured":"Pastori D, Pignatelli P, Farcomeni A, Cangemi R, Hiatt WR, Bartimoccia S, Nocella C, Vicario T, Bucci T, Carnevale R et al (2015) Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation. Am Heart J 170(3):490\u2013497e491. https:\/\/doi.org\/10.1016\/j.ahj.2015.05.011","journal-title":"Am Heart J"},{"issue":"2","key":"3356_CR44","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.jtha.2024.10.025","volume":"23","author":"A Polzin","year":"2025","unstructured":"Polzin A, Benkhoff M, Thienel M, Barcik M, Mourikis P, Shchurovska K, Helten C, Ehreiser V, Zhe Z, von Wulffen F et al (2025) Long-term FXa inhibition attenuates thromboinflammation after acute myocardial infarction and stroke by platelet proteome alteration. J Thromb Haemost 23(2):668\u2013683. https:\/\/doi.org\/10.1016\/j.jtha.2024.10.025","journal-title":"J Thromb Haemost"},{"issue":"12","key":"3356_CR45","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.amjcard.2013.08.027","volume":"112","author":"R Artang","year":"2013","unstructured":"Artang R, Rome E, Nielsen JD, Vidaillet HJ (2013) Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol 112(12):1973\u20131979. https:\/\/doi.org\/10.1016\/j.amjcard.2013.08.027","journal-title":"Am J Cardiol"},{"issue":"2","key":"3356_CR46","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11239-012-0857-9","volume":"35","author":"B Dale","year":"2013","unstructured":"Dale B, Eikelboom JW, Weitz JI, Young E, Paikin JS, Coppens M, Whitlock RP, Connolly SJ, Ginsberg JS, Hirsh J (2013) Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis 35(2):295\u2013301. https:\/\/doi.org\/10.1007\/s11239-012-0857-9","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"3356_CR47","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1160\/TH11-06-0382","volume":"106","author":"T Furugohri","year":"2011","unstructured":"Furugohri T, Sugiyama N, Morishima Y, Shibano T (2011) Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system. Thromb Haemost 106(6):1076\u20131083. https:\/\/doi.org\/10.1160\/TH11-06-0382","journal-title":"Thromb Haemost"},{"issue":"3","key":"3356_CR48","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1046\/j.1538-7836.2003.00060.x","volume":"1","author":"P Klement","year":"2003","unstructured":"Klement P, Carlsson S, Rak J, Liao P, Vlasin M, Stafford A, Johnston M, Weitz JI (2003) The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model. J Thromb Haemost 1(3):587\u2013594. https:\/\/doi.org\/10.1046\/j.1538-7836.2003.00060.x","journal-title":"J Thromb Haemost"},{"issue":"2","key":"3356_CR49","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1055\/s-0040-1716750","volume":"121","author":"A Polzin","year":"2021","unstructured":"Polzin A, Dannenberg L, Thienel M, Orban M, Wolff G, Hohlfeld T, Zeus T, Kelm M, Petzold T (2021) Noncanonical effects of oral Thrombin and factor Xa inhibitors in platelet activation and arterial thrombosis. Thromb Haemost 121(2):122\u2013130. https:\/\/doi.org\/10.1055\/s-0040-1716750","journal-title":"Thromb Haemost"},{"issue":"4","key":"3356_CR50","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/00365513.2024.2369993","volume":"84","author":"VS Taune","year":"2024","unstructured":"Taune VS, Zabczyk M, He S, Agren A, Blomback M, Wallen H, Skeppholm M (2024) Effects of dabigatran, rivaroxaban, and apixaban on fibrin network permeability, thrombin generation, and fibrinolysis. Scand J Clin Lab Invest 84(4):257\u2013267. https:\/\/doi.org\/10.1080\/00365513.2024.2369993","journal-title":"Scand J Clin Lab Invest"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03356-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03356-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03356-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:23:19Z","timestamp":1783621399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03356-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":50,"alternative-id":["3356"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03356-7","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"16 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"G.R.: Research grants\/contracts from Bayer, BMS-Janssen; lecture fees from Bayer, Boehringer Ingelheim, Daiichi-Sankyo and Menarini. R.M.: Lecture and Advisory Board fees from: Novartis, Daichi-Sankyo, Amgen, Viatris, Werfen, Sanofi, Menarini, Eli-Lilly. R.D.C.: fees, honoraria and research funding from Sanofi-Aventis, Boehringer Ingelheim, Bayer, BMS\/Pfizer, Daiichi-Sankyo, Novartis, Merck, Portola, Roche, Astra Zeneca, Menarini, Guidotti, Milestone, Amarin, Noventure, Amgen. The other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}